AOD 9604 for weight loss: what the evidence actually shows

What did @bruna_oak actually say?

Honestly, not much that's decipherable. The transcript is either a translation artifact or a garbled auto-caption of what appears to be a Portuguese-language promotional video for a company called Geolab Peptide. The clearest line is an apparent self-introduction and product display: "I will show you some of the products that you have already seen." The caption does the real talking, pairing AOD 9604 with the hashtags weightloss and gh, strongly implying this peptide delivers fat-loss results tied to growth hormone activity. That framing is what we're actually fact-checking here.

The video appears to be promotional content for @glabpeptides, a supplier shipping within the US. No specific dosing, mechanism, or clinical outcome is stated in the transcript, but the hashtag and product association do the implied work. Influencer marketing often operates this way: the claim lives in the context, not the words.

Does the science back up the AOD 9604 fat-loss claim?

Partially, but the picture is much messier than a TikTok caption suggests. AOD 9604 is a synthetic peptide fragment (hGH 176-191) derived from the C-terminus of human growth hormone. Early animal studies were genuinely promising. Ng et al. (2000, Journal of Endocrinology) showed the fragment reduced fat mass in obese rodent models without the glucose-disrupting effects of full hGH. That's the hook the peptide community ran with.

The problem is translation to humans. Metabolic Pharmaceuticals ran phase 2 and phase 3 trials for AOD 9604 as an obesity drug (branded Tbodies) in the early 2000s. The phase 3 results were disappointing enough that the drug never received FDA approval. A 2004 summary by Heffernan et al. (European Journal of Pharmacology) noted the peptide showed no statistically significant weight loss benefit over placebo in larger human trials. WADA added it to its prohibited list in 2014, which gives it a performance-enhancement reputation its human clinical data doesn't fully support.

What did they get wrong, and what did they get right?

What they got right: AOD 9604 does have a legitimate research history. It is not a made-up wellness compound. The growth hormone fragment concept has real biochemical logic, and the early animal data on lipolysis is real.

What they got wrong, or at least incomplete: Implying this is an established fat-loss tool for humans ignores the failed phase 3 trials. Selling it under a fitness and weight-loss framing, without any of that context, misleads viewers into thinking the science is settled. It isn't. The peptide is also not FDA-approved for any indication. It exists in a regulatory gray zone, compounded and sold without the clinical evidence required for a drug approval. Presenting it as simply a "benefit" product skips over the part where the benefit hasn't been reliably proven in humans at scale.

The promotional angle for a specific supplier adds another layer of concern. No disclosure of financial relationship is visible in the transcript.

What should you actually know about AOD 9604?

A few things worth keeping straight. First, AOD 9604 is not the same as growth hormone, and it doesn't have growth hormone's full anabolic or insulin-disrupting profile. That's actually why researchers were interested in it. But "fewer side effects than HGH" is not the same as "proven to work in humans."

Second, compounded versions of peptides like this are not FDA-approved drugs. Their purity, potency, and sterility depend entirely on the compounding pharmacy's practices. The FDA has raised concerns about compounded peptides specifically. Third, WADA prohibition means anyone in tested sport using this is at real risk. Fourth, if you're considering any peptide therapy, the conversation belongs with a licensed clinician who can review your labs, not a TikTok supplier account. The hashtag weightloss attached to an unapproved injectable compound deserves more skepticism than 19,800 views suggests most people applied.